SBIR-STTR Award

Medical Capability Simulator Interface Tool for OneSAF
Award last edited on: 5/16/2011

Sponsored Program
SBIR
Awarding Agency
DOD : OSD
Total Award Amount
$99,975
Award Phase
1
Solicitation Topic Code
OSD09-H16
Principal Investigator
Paul Cox

Company Information

PERL Research LLC

3414-A Governors Drive
Huntsville, AL 35805
   (256) 539-5364
   N/A
   www.perlresearch.com
Location: Single
Congr. District: 05
County: Madison

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2010
Phase I Amount
$99,975
Despite these advances, simulation models have lacked advancement for emerging medical technologies within the operational simulation system most prevalent at Army Battle Labs, i.e. OneSAF (Simulated Autonomous Forces). In addition, there are no combat casualty or patient models within OneSAF that can be used to assess or evaluate the effectiveness of a new medical technology or treatment technique when used by a combat life saver or combat medic during small unit maneuver exercises or simulations. Simulation technology is critical in evaluating new technology and how it will develop better tactics and train soldiers. The ultimate goal of these simulations is to have the best fielded medical technology and the best trained soldier to help reduce the number of casualties. In order to address this limitation, PERL Research and Lockheed Martin propose the development of a Medical Capability Simulator Interface Tool for OneSAF. The resulting tool will allow medical technologies to be assessed and evaluated at Army Battle Labs within tactical exercises and simulations. Our approach will allow output data for after action reports (AAR) along with analysis tools to allow assessment of the simulations which can support the development of tactics, techniques, and procedures (TTPs).

Keywords:
Onesaf, Modeling And Simulation, Medical Technology, Combat Casualty, Battle Lab, Lstat-Lite, First Responder

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----